This is Palatine's Typepad Profile.
Join Typepad and start following Palatine's activity
Join Now!
Already a member? Sign In
Palatine
Recent Activity
Update on bb2121, Potential Advanced Multiple Myeloma Therapy, Set for ASCO 2018 Celgene’s investigational and second-generation CAR T-cell therapy bb2121 is showing real promise in treating advanced multiple myeloma patients, those with relapsed or refractory disease, updated Phase 1 data is expected to show. An earlier analsyis showed that, among... Continue reading
Posted May 24, 2018 at MMDevelopments
Xgeva Approved to Prevent Skeletal-Related Events in Multiple Myeloma Patients (1/5/18) http://bit.ly/2qDgYea The FDA approval was supported by data from the Phase 3, randomized, double-blind, multicenter '482 study (n=1,718) that compared Xgeva with zoledronic acid for the prevention of skeletal-related events in adults with newly diagnosed multiple myeloma and bone... Continue reading
Posted Jan 7, 2018 at MMDevelopments
Gene Therapy Shows Potential in Multiple Myeloma Trials (12/19/17) http://bit.ly/2BZztyU Investigation of the efficacy of a CAR T cell treatment administered after chemotherapy elicited a response in 64% of patients. In another study, patients received an infusion of a monoclonal antibody, leading to a 60% response rate. Continue reading
Posted Dec 27, 2017 at MMDevelopments
Myeloma Therapy Gets FDA Breakthrough Therapy Designation (11/2/17) http://bit.ly/2h60s2q Breakthrough Therapy Designation from the U.S. Food and Drug Administration for an antibody to treat patients with multiple myeloma who have failed at least three prior lines of therapy. Continue reading
Posted Nov 2, 2017 at MMDevelopments
Hematology Masters in Multiple Myeloma: A Video Roundtable (9/14/17) http://bit.ly/2wehduJ Discussion takes the learner through an overview of smoldering myeloma to management of relapsed disease. Continue reading
Posted Sep 24, 2017 at MMDevelopments
Vaccines Targeting Multiple Myeloma Offer Promising Therapeutic Approach (6/21/17) http://bit.ly/2uDCNr1 Numerous investigational strategies are under development for overcoming immune evasion, including candidate myeloma vaccines. Continue reading
Posted Jul 3, 2017 at MMDevelopments
CAR-T Cancer Approach Has Surprising Success in Multiple Myeloma (6/5/17) http://nbcnews.to/2ruAGXR Doctors are reporting unprecedented success from a new cell and gene therapy for multiple myeloma, a blood cancer that's on the rise. Although it's early and the study is small -- 35 people -- every patient responded and all... Continue reading
Posted Jun 17, 2017 at MMDevelopments
Bortezomib-Induced Neuropathy From First to Second Treatment for Multiple Myeloma (5/17/17) http://bit.ly/2rftgbE Bortezomib-induced peripheral neuropathy (BIPN) does not worsen between initial treatment and retreatment in patients with multiple myeloma. FDA Clears Study Of GBR 1342 For Multiple Myeloma (5/15/17) http://bit.ly/2qnMqsf The FDA cleared Glenmark Pharmaceuticals’ investigational new drug application to... Continue reading
Posted May 26, 2017 at MMDevelopments
Multiple Myeloma Drug Resistance: New Immunotherapies May Improve Survival (5/4/17) http://bit.ly/2qNpOlq Immunotherapy should be particularly well-suited to treating multiple myeloma, due to the number of cell surface markers on myeloma cells that are unique. Although multiple myeloma is still widely considered incurable for most patients, as immunotherapy research matures, that... Continue reading
Posted May 6, 2017 at MMDevelopments
FDA grants orphan drug designation to tasquinimod for multiple myeloma (4/13/17) http://bit.ly/2qg5jwQ Tasquinimod (Active Biotech) is an immunomodulatory, antimetastatic and antiangiogenic compound that affects a tumor’s ability to grow and spread. New Algorithm to Successfully Identify Gene Sets that are Informative of Cancer Treatment Specific Survival (4/10/17) http://prn.to/2pmOgvG SkylineDx has... Continue reading
Posted Apr 26, 2017 at MMDevelopments
Oncolytics Biotech® Inc. Enters into First-in-Class Collaboration with Myeloma UK and Celgene Using REOLYSIN® in Combination with Imnovid® or Revlimid® in Patients with Myeloma (3/16/17) http://bit.ly/2nJ0L0z Oncolytics Biotech introduces a novel way of activating a patient's own immune system to target their myeloma (immunotherapy) using a natural virus and lenalidomide... Continue reading
Posted Mar 26, 2017 at MMDevelopments
Using A Rabbit Virus To Treat Multiple Myeloma (2/21/17) http://bit.ly/2kQAn84 Treating multiple myeloma (MM) with myxoma virus (MYXV) eliminated a majority of malignant cells in preclinical studies, report investigators. Furthermore, introduction of MYXV had no impact on the bone marrow compartment and elicited a strong immune response that eradicated disease... Continue reading
Posted Feb 26, 2017 at MMDevelopments
Oxis Biotech Announces U.S. Patent and Trademark Office Notification of Patent Issuance for Oxis-4235 as Treatment for Multiple Myeloma (2/21/17) https://yhoo.it/2mij63W The drug is intended to stop the growth of multiple myeloma cells without harming healthy cells. In addition to shrinking the tumors, the dual purpose drug is also intended... Continue reading
Posted Feb 21, 2017 at MMDevelopments
No Association Between Response Rates and Survival in Newly Diagnosed Multiple Myeloma (2/14/17) http://bit.ly/2kSMkZx There was no association between conventional response outcomes, such as complete response (CR) or very good partial response (VGPR), and survival in patients with newly diagnosed multiple myeloma, according to the results of a meta-regression analysis... Continue reading
Posted Feb 19, 2017 at MMDevelopments
Selinexor for Relapsed/Refractory Multiple Myeloma (2/2/17) http://bit.ly/2lbsPsk Patients with relapsed/refractory multiple myeloma (RRMM) for whom prior treatment with lenalidomide, pomalidomide, bortezomib, and carfilzomib fail have few treatment options. Selinexor (KPT-330) is a selective inhibitor of nuclear export (SINE) under development for the treatment of RRMM and other advanced hematologic malignancies.... Continue reading
Posted Feb 5, 2017 at MMDevelopments
Cellular Immunotherapy for Multiple Myeloma Advancing Rapidly (1/30/17) http://wb.md/2jxdZjz Potentially curative therapies for multiple myeloma (MM) based on various methods of adoptive immune cell transfer are advancing rapidly in clinical trials. The activity of these strategies in the clinical setting, although experimental, can no longer be considered hypothetical. Continue reading
Posted Feb 1, 2017 at MMDevelopments
Targeting Genetic Alterations in Multiple Myeloma May Suppress Tumor Growth, Study Suggests (1/16/17) http://bit.ly/2iYoqrc Research suggests that inhibiting the enzyme responsible for the DNA modifications may be a promising approach to treating myeloma patients. Current Strategies for the Immunotherapy of Multiple Myeloma (1/15/17) http://bit.ly/2jL9nF8 Here we outline the most promising... Continue reading
Posted Jan 21, 2017 at MMDevelopments
New CAR T-Cell Therapy Promising for Multiple Myeloma (1/5/17) http://bit.ly/2j9FwnL An experimental chimeric antigen receptor (CAR) T-cell therapy may be effective in treating multiple myeloma without the risk for severe cytokine release syndrome (CRS) associated with other CAR T-cell therapies, according to investigators. Continue reading
Posted Jan 13, 2017 at MMDevelopments
Cancer Statistics Report: Death Rate Down 23% in 21 Years (1/7/16) http://bit.ly/1kQ0cjE Annual statistics reporting from the American Cancer Society shows the death rate from cancer in the US has declined steadily over the past 2 decades. Continue reading
Posted Jan 6, 2017 at MMDevelopments
Venetoclax Active in Heavily Treated Multiple Myeloma (12/21/16) http://bit.ly/2i2NmB4 “we have a drug that can change the outcome for a lot of patients with myeloma. It may be the first drug that is actually going to be a biomarker-driven drug in this disease.” Aduro Presents Positive Results on BION-1301 for... Continue reading
Posted Dec 27, 2016 at MMDevelopments
Daratumumab Associated With Deep Clinical Response In Relapsed, Refractory Multiple Myeloma (12/4/16) http://bit.ly/2hj53MQ The addition of daratumumab to standard-of-care therapies for relapsed or refractory multiple myeloma conferred significant reductions in minimal residual disease, according to an analysis of the POLLUX and CASTOR studies presented at the ASH Annual Meeting and... Continue reading
Posted Dec 11, 2016 at MMDevelopments
Could a cow virus help fight multiple myeloma? (11/21/16) http://bit.ly/2geetX7 Engineered forms of two bovine viruses are being examined for their potential to treat multiple myeloma In patients with multiple myeloma, thalidomide may cause toxic epidermal necrolysis (TEN) (11/18/16) http://bit.ly/2fVRxOa New research shows that excess weight increases the risk that... Continue reading
Posted Nov 24, 2016 at MMDevelopments
Denosumab (Xgeva) is noninferior to zoledronic acid (Zometa) at delaying skeletal-related events (SREs) (10/21/16) http://bit.ly/2eZeE6y Denosumab (Xgeva) is noninferior to zoledronic acid (Zometa) at delaying skeletal-related events (SREs) for patients with multiple myeloma, according to topline findings from the phase III 482 study released by the developer of RANK ligand... Continue reading
Posted Oct 28, 2016 at MMDevelopments
Stellas' Multiple Myeloma Phase 2 Trial Provides Positive Results (10/13/16) http://bit.ly/2es7I2F Sellas Life Sciences Group provided positive results from their phase II study of WT1 first-in-class immunotherapeutic anti-cancer treatment in multiple myeloma (MM) patients who have had an autologous stem cell transplantation (ASCT). The 19 patients enrolled in the study... Continue reading
Posted Oct 18, 2016 at MMDevelopments
Researchers Take Step Toward Understanding How Multiple Myeloma Takes Hold (10/3/16) http://bit.ly/2dTGAgK Israeli scientists are moving closer to understanding how multiple myeloma takes hold in bone marrow by identifying what they believe are the mechanisms used by cancer cells to take over. Triplet Therapy, ASCT Frontline Standard for Multiple Myeloma... Continue reading
Posted Oct 7, 2016 at MMDevelopments